• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

超声心动图应变异常先于肥厚型心肌病突变携带者左心室肥厚的发展。

Echocardiographic Strain Abnormalities Precede Left Ventricular Hypertrophy Development in Hypertrophic Cardiomyopathy Mutation Carriers.

机构信息

Department of Advanced Biomedical Sciences, Federico II University of Naples, Via S Pansini 5, 80131 Napoli, Italy.

Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.

出版信息

Int J Mol Sci. 2024 Jul 25;25(15):8128. doi: 10.3390/ijms25158128.

DOI:10.3390/ijms25158128
PMID:39125703
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11312232/
Abstract

Hypertrophic cardiomyopathy (HCM) is a genetic disease characterized by unexplained left ventricular hypertrophy (LVH), diastolic dysfunction, and increased sudden-death risk. Early detection of the phenotypic expression of the disease in genetic carriers without LVH (Gen+/Phen-) is crucial for emerging therapies. This clinical study aims to identify echocardiographic predictors of phenotypic development in Gen+/Phen-. Sixteen Gen+/Phen- (one subject with troponin T, six with myosin heavy chain-7, and nine with myosin-binding protein C3 mutations), represented the study population. At first and last visit we performed comprehensive 2D speckle-tracking strain echocardiography. During a follow-up of 8 ± 5 years, five carriers developed LVH (LVH+). At baseline, these patients were older than those who did not develop LVH (LVH-) (30 ± 8 vs. 15 ± 8 years, = 0.005). LVH+ had reduced peak global strain rate during the isovolumic relaxation period (SRIVR) (0.28 ± 0.05 vs. 0.40 ± 0.11 1/s, = 0.048) and lower global longitudinal strain (GLS) (-19.8 ± 0.4 vs. -22.3 ± 1.1%; < 0.0001) than LVH- at baseline. SRIVR and GLS were not correlated with age (overall, > 0.08). This is the first HCM study investigating subjects before they manifest clinically significant or relevant disease burden or symptomatology, comparing at baseline HCM Gen+/Phen- subjects who will develop LVH with those who will not. Furthermore, we identified highly sensitive, easily obtainable, age- and load-independent echocardiographic predictors of phenotype development in HCM gene carriers who may undergo early preventive treatment.

摘要

肥厚型心肌病(HCM)是一种遗传性疾病,其特征为左心室肥厚(LVH)、舒张功能障碍和猝死风险增加。在没有 LVH(Gen+/Phen-)的遗传携带者中早期发现疾病表型表达对于新兴疗法至关重要。本临床研究旨在确定 Gen+/Phen-中表型发展的超声心动图预测因子。16 名 Gen+/Phen-(一名肌钙蛋白 T 阳性,六名肌球蛋白重链-7 阳性,九名肌球蛋白结合蛋白 C3 突变阳性)代表研究人群。在首次和末次就诊时,我们进行了全面的二维斑点追踪应变超声心动图检查。在 8±5 年的随访期间,五名携带者出现 LVH(LVH+)。在基线时,这些患者比未发生 LVH(LVH-)的患者年龄更大(30±8 岁比 15±8 岁, =0.005)。LVH+在等容舒张期的峰值整体应变率(SRIVR)(0.28±0.05 比 0.40±0.11 1/s, =0.048)和整体纵向应变(GLS)(-19.8±0.4 比-22.3±1.1%;<0.0001)均低于 LVH-。SRIVR 和 GLS 与年龄无相关性(总体,>0.08)。这是第一项在出现临床显著或相关疾病负担或症状之前研究 HCM 的研究,比较了基线时将发生 LVH 的 HCM Gen+/Phen-受试者与不会发生 LVH 的受试者。此外,我们确定了在可能接受早期预防性治疗的 HCM 基因携带者中,具有高度敏感性、易于获得、与年龄和负荷无关的表型发展的超声心动图预测因子。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddfa/11312232/7d329abd014f/ijms-25-08128-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddfa/11312232/83f3abdd7330/ijms-25-08128-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddfa/11312232/c6b301565bd3/ijms-25-08128-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddfa/11312232/7d329abd014f/ijms-25-08128-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddfa/11312232/83f3abdd7330/ijms-25-08128-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddfa/11312232/c6b301565bd3/ijms-25-08128-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddfa/11312232/7d329abd014f/ijms-25-08128-g003.jpg

相似文献

1
Echocardiographic Strain Abnormalities Precede Left Ventricular Hypertrophy Development in Hypertrophic Cardiomyopathy Mutation Carriers.超声心动图应变异常先于肥厚型心肌病突变携带者左心室肥厚的发展。
Int J Mol Sci. 2024 Jul 25;25(15):8128. doi: 10.3390/ijms25158128.
2
Could two-dimensional radial strain be considered as a novel tool to identify pre-clinical hypertrophic cardiomyopathy mutation carriers?二维径向应变可否被视为一种新型工具,用于识别临床前肥厚型心肌病突变携带者?
Int J Cardiovasc Imaging. 2019 Dec;35(12):2167-2175. doi: 10.1007/s10554-019-01668-9. Epub 2019 Jul 18.
3
Association of variants in MYH7, MYBPC3 and TNNT2 with sudden cardiac death-related risk factors in Brazilian patients with hypertrophic cardiomyopathy.MYH7、MYBPC3 和 TNNT2 变异与巴西肥厚型心肌病患者与心源性猝死相关危险因素的关联。
Forensic Sci Int Genet. 2021 May;52:102478. doi: 10.1016/j.fsigen.2021.102478. Epub 2021 Feb 3.
4
Echocardiographic strain imaging to assess early and late consequences of sarcomere mutations in hypertrophic cardiomyopathy.超声心动图应变成像评估肥厚型心肌病肌节突变的早期和晚期后果。
Circ Cardiovasc Genet. 2009 Aug;2(4):314-21. doi: 10.1161/CIRCGENETICS.109.862128. Epub 2009 Jun 19.
5
A Long Term Follow-up Study of Carriers of Hypertrophic Cardiomyopathy Mutations.肥厚型心肌病突变携带者的长期随访研究
Heart Lung Circ. 2017 Jan;26(1):18-24. doi: 10.1016/j.hlc.2016.04.019. Epub 2016 May 20.
6
Comparison of echocardiographic and cardiac magnetic resonance imaging in hypertrophic cardiomyopathy sarcomere mutation carriers without left ventricular hypertrophy.肥厚型心肌病肌节突变携带者无左心室肥厚时超声心动图与心脏磁共振成像的比较
Circ Cardiovasc Genet. 2013 Jun;6(3):230-7. doi: 10.1161/CIRCGENETICS.113.000037. Epub 2013 May 20.
7
Assessment of myocardial oxygenation, strain, and diastology in MYBPC3-related hypertrophic cardiomyopathy: a cardiovascular magnetic resonance and echocardiography study.评估 MYBPC3 相关肥厚型心肌病的心肌氧合、应变和舒张功能:心血管磁共振和超声心动图研究。
Eur Heart J Cardiovasc Imaging. 2019 Aug 1;20(8):932-938. doi: 10.1093/ehjci/jey220.
8
Subclinical echocardiographic abnormalities in phenotype-negative carriers of myosin-binding protein C3 gene mutation for hypertrophic cardiomyopathy.表型阴性的肌球蛋白结合蛋白 C3 基因突变致肥厚型心肌病患者的亚临床超声心动图异常。
Am Heart J. 2011 Aug;162(2):262-267.e3. doi: 10.1016/j.ahj.2011.05.018. Epub 2011 Jul 18.
9
Comparing echocardiographic characteristics in genotype positive-phenotype positive hypertrophic cardiomyopathy and hypertensive left ventricular hypertrophy.比较基因型阳性-表型阳性肥厚型心肌病与高血压性左心室肥厚的超声心动图特征。
Eur Heart J Cardiovasc Imaging. 2022 Feb 22;23(3):340-348. doi: 10.1093/ehjci/jeab217.
10
Hypertrophic cardiomyopathy in myosin-binding protein C () Icelandic founder mutation carriers.肌球蛋白结合蛋白C()冰岛始祖突变携带者中的肥厚型心肌病
Open Heart. 2020 Apr 5;7(1):e001220. doi: 10.1136/openhrt-2019-001220. eCollection 2020.

引用本文的文献

1
Genetic insights into hypertrophic cardiomyopathy: pathogenesis, diagnosis, and therapeutic implications.肥厚型心肌病的遗传学见解:发病机制、诊断及治疗意义
J Cardiovasc Imaging. 2025 Jul 21;33(1):9. doi: 10.1186/s44348-025-00055-4.
2
Unveiling the complexity of nonobstructive hypertrophic cardiomyopathy.揭示非梗阻性肥厚型心肌病的复杂性。
Heart Fail Rev. 2025 Jun 14. doi: 10.1007/s10741-025-10535-w.
3
Mexican guidelines 2024 for the diagnosis and treatment of hypertrophic cardiomyopathy.《2024年墨西哥肥厚型心肌病诊断与治疗指南》

本文引用的文献

1
Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial.亚临床肥厚型心肌病的心脏重构:VANISH 随机临床试验。
JAMA Cardiol. 2023 Nov 1;8(11):1083-1088. doi: 10.1001/jamacardio.2023.2808.
2
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2020 年 AHA/ACC 肥厚型心肌病患者诊断与治疗指南:概要:美国心脏病学会/美国心脏协会联合临床实践指南委员会的报告。
J Am Coll Cardiol. 2020 Dec 22;76(25):3022-3055. doi: 10.1016/j.jacc.2020.08.044. Epub 2020 Nov 20.
3
Arch Cardiol Mex. 2024;94(Supl 4):1-75. doi: 10.24875/ACM.M25000098.
Left Ventricular Mass in Hypertrophic Cardiomyopathy Assessed by 2D-Echocardiography: Validation with Magnetic Resonance Imaging.
二维超声心动图评估肥厚型心肌病的左心室质量:与磁共振成像的对照研究。
J Cardiovasc Transl Res. 2020 Apr;13(2):238-244. doi: 10.1007/s12265-019-09911-3. Epub 2019 Sep 5.
4
Genetic Pathogenesis of Hypertrophic and Dilated Cardiomyopathy.肥厚型和扩张型心肌病的遗传发病机制
Heart Fail Clin. 2018 Apr;14(2):139-146. doi: 10.1016/j.hfc.2017.12.004.
5
Interacting-heads motif has been conserved as a mechanism of myosin II inhibition since before the origin of animals.交互头基 motif 作为肌球蛋白 II 抑制的一种机制,在动物起源之前就已经保守下来。
Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):E1991-E2000. doi: 10.1073/pnas.1715247115. Epub 2018 Feb 14.
6
Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.肥厚型心肌病:遗传学、发病机制、临床表现、诊断与治疗
Circ Res. 2017 Sep 15;121(7):749-770. doi: 10.1161/CIRCRESAHA.117.311059.
7
The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet Study.肥厚型心肌病突变携带者的早期表型负担和壁厚度的影响:来自 HCMNet 研究的发现。
JAMA Cardiol. 2017 Apr 1;2(4):419-428. doi: 10.1001/jamacardio.2016.5670.
8
Clinical and Mechanistic Insights Into the Genetics of Cardiomyopathy.心肌病遗传学的临床与机制见解
J Am Coll Cardiol. 2016 Dec 27;68(25):2871-2886. doi: 10.1016/j.jacc.2016.08.079.
9
Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.超声心动图评估左心室舒张功能的建议:美国超声心动图学会和欧洲心血管影像学会的更新
Eur Heart J Cardiovasc Imaging. 2016 Dec;17(12):1321-1360. doi: 10.1093/ehjci/jew082. Epub 2016 Jul 15.
10
Reasons for Using Electronic Cigarettes and Intentions to Quit Among Electronic Cigarette Users in Malaysia.马来西亚电子烟使用者使用电子烟的原因及戒烟意愿
J Community Health. 2016 Dec;41(6):1101-1109. doi: 10.1007/s10900-016-0196-4.